KRAS and metastatic colorectal cancer: In light of these findings, the American Society of Clinical Oncology (ASCO) recommends testing both the EGFR and KRAS mutation status in patients with metastatic colorectal cancer who are candidates for anti-EGFR antibody therapy [38].